scholarly journals Diagnostic Performance of 18F-FDG PET/CT in Infectious and Inflammatory Diseases according to Published Meta-Analyses

2019 ◽  
Vol 2019 ◽  
pp. 1-12 ◽  
Author(s):  
Giorgio Treglia
Keyword(s):  
Infectious Diseases ◽  
Fdg Pet ◽  
Diagnostic Performance ◽  
Inflammatory Diseases ◽  
Cochrane Library ◽  
Imaging Method ◽  
Evidence Based ◽  
Pet Ct ◽  
Meta Analyses ◽  
Fdg Pet Ct

Purpose. To date, several meta-analyses have reported data about the diagnostic performance of 18F-FDG PET/CT in infectious and inflammatory diseases. This article aims to summarize the published evidence-based data about the diagnostic performance of 18F-FDG PET/CT in this setting. Methods. A comprehensive computer literature search of meta-analyses published in PubMed/MEDLINE and Cochrane library database from January 2009 through December 2018 and regarding the diagnostic performance of 18F-FDG PET/CT in infectious and inflammatory diseases was carried out. This combination of key words was used: (i) “PET” OR “positron emission tomography” OR “FDG” OR “fluorodeoxyglucose” AND (ii) meta-analysis. Only records on inflammatory or infectious diseases were selected. Results. The diagnostic performance of 18F-FDG PET/CT in detecting inflammatory and infectious diseases has been summarized taking into account 36 meta-analyses published in the literature. Evidence-based data demonstrated good diagnostic performance of 18F-FDG PET/CT for several inflammatory and infectious diseases, in particular cardiovascular infectious and inflammatory diseases and some musculoskeletal infections. Conclusions. Evidence-based data about the diagnostic performance of 18F-FDG PET/CT in infectious and inflammatory diseases are increasing, with good diagnostic performance of this imaging method for some indications. More prospective multicenter studies and cost-effective analyses are warranted.

scholarly journals Diagnostic Performance of PET or PET/CT with Different Radiotracers in Patients with Suspicious Lung Cancer or Pleural Tumours according to Published Meta-Analyses

2020 ◽  
Vol 2020 ◽  
pp. 1-7 ◽  
Author(s):  
Filippo Lococo ◽  
Barbara Muoio ◽  
Marco Chiappetta ◽  
Dania Nachira ◽  
Leonardo Petracca Ciavarella ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Positron Emission Tomography ◽  
Fdg Pet ◽  
Diagnostic Performance ◽  
Emission Tomography ◽  
Evidence Based ◽  
Positron Emission ◽  
Pet Ct ◽  
Meta Analyses ◽  
Fdg Pet Ct

Purpose. Several meta-analyses have reported data about the diagnostic performance of positron emission tomography or positron emission tomography/computed tomography (PET or PET/CT) with different radiotracers in patients with suspicious lung cancer (LC) or pleural tumours (PT). This review article aims at providing an overview on the recent evidence-based data in this setting. Methods. A comprehensive literature search of meta-analyses published in PubMed/MEDLINE and Cochrane Library database from January 2010 through March 2020 about the diagnostic performance of PET or PET/CT with different radiotracers in patients with suspicious LC or PT was performed. This combination of keywords was used: (A) “PET” OR “positron emission tomography” AND (B) “lung” OR “pulmonary” OR “pleur∗” AND (C) meta-analysis. Only meta-analyses on PET or PET/CT in patients with suspicious LC or PT were selected. Results. We have summarized the diagnostic performance of PET or PET/CT with fluorine-18 fluorodeoxyglucose (18F-FDG) and other radiotracers taking into account 17 meta-analyses. Evidence-based data demonstrated a good diagnostic performance of 18F-FDG PET or PET/CT for the characterization of solitary pulmonary nodules (SPNs) or pleural lesions with overall higher sensitivity than specificity. Evidence-based data do not support the routine use of dual time point (DTP) 18F-FDG PET/CT or fluorine-18 fluorothymidine (18F-FLT) PET/CT in the differential diagnosis of SPNs. Even if 18F-FDG PET/CT has high sensitivity and specificity as a selective screening modality for LC, its role in this setting remains unknown. Conclusions. Evidence-based data about the diagnostic performance of PET/CT with different radiotracers for suspicious LC or PT are increasing, with good diagnostic performance of 18F-FDG PET/CT. More prospective multicenter studies and cost-effectiveness analyses are warranted.

scholarly journals IPET-CT in inflammatory diseases of kidneys and bladder: diagnostic efficacy

2021 ◽  
Vol 9 (4) ◽  
pp. 13-20
Author(s):  
V. B. Berdichevsky ◽  
B. A. Berdichevsky ◽  
A. V. Romanova ◽  
F. R. Rasulov ◽  
A. A. Naletov ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Inflammatory Diseases ◽  
Whole Body ◽  
Imaging Method ◽  
Partial Recovery ◽  
Diagnostic Efficacy ◽  
Radiation Cystitis ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Introduction. The incorporation of combined positron emission tomography-computed tomography (PET-CT) into clinical practice has significantly expanded the understanding of the pathogenesis of many diseases. Evidence-based data on the diagnostic efficacy in infectious and inflammatory diseases is increasing, making this imaging method very promising. Purpose of the study. To study the diagnostic efficacy of 18F-FDG PET-CT in various chronic inflammatory diseases of kidneys and bladder.Materials and methods. A retrospective study of the results of whole-body 18F-FDG PET-CT in 45 patients was carried out. Patients underwent an investigation at various times after surgical treatment of localized oncology of the anogenital zone at the T1N0M0 stage without the involvement of the genitourinary system. It was found that 24 patients had a history of chronic pyelonephritis and 21 patients had manifestations of radiation cystitis. Repeated PET/CT scans were performed after a course of therapy for inflammatory urological diseases to assess the treatment results of the underlying pathology.Results. The latent course of chronic renal failure was accompanied by a diffuse decrease in 18F-FDG metabolism in the renal parenchyma with its partial recovery after etiotropic therapy and urine sanitation. Hypermetabolism of 18F-FDG was detected in the bladder wall during manifestations of radiation cystitis, which was leveled during therapy and relief of urinary syndrome manifestations. Bacterial and radiation inflammation differed in molecular-cell responses to the pathogen, while the results of urinalysis, indicating the effectiveness of the treatment, coincided with the visual and digital indicators of the restoration of adequate energy metabolism in the studied tissues.Conclusions. Metabolism of 18F-FDG in the kidneys and bladder can objectively reflect the nature of inflammation and complement the data on the effectiveness of the treatment.

scholarly journals Diagnostic performance of PET in thyroid cancer with elevated anti-Tg Ab

2018 ◽  
Vol 25 (6) ◽  
pp. 643-652 ◽  
Author(s):  
Seong-Jang Kim ◽  
Sang-Woo Lee ◽  
Kyoungjune Pak ◽  
Sung-Ryul Shim
Keyword(s):  
Thyroid Cancer ◽  
Likelihood Ratio ◽  
Fdg Pet ◽  
Diagnostic Performance ◽  
Positive Likelihood Ratio ◽  
Negative Likelihood Ratio ◽  
Whole Body ◽  
Cochrane Library ◽  
Pet Ct ◽  
Fdg Pet Ct

We aimed to explore the role of the diagnostic accuracy of F-18 fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) for the detection of recurrent and/or metastatic diseases in differentiated thyroid cancer (DTC) patients with progressively and/or persistently elevated TgAb levels and negative radioactive iodine whole-body scan (RI-WBS) through a systematic review and meta-analysis. The MEDLINE, EMBASE and Cochrane Library database, from the earliest available date of indexing through June 30, 2017, were searched for studies evaluating the diagnostic performance of F-18 FDG PET/CT for the detection of recurrent and/or metastatic diseases in DTC patients with progressively and/or persistently elevated TgAb levels and negative RI-WBS. We determined the sensitivities and specificities across studies, calculated positive and negative likelihood ratios (LR+ and LR−). Across 9 studies (515 patients), the pooled sensitivity for F-18 FDG PET/CT was 0.84 (95% CI; 0.77–0.89) a pooled specificity of 0.78 (95% CI; 0.67–0.86). Likelihood ratio (LR) syntheses gave an overall positive likelihood ratio (LR+) of 3.8 (95% CI; 2.5–5.7) and negative likelihood ratio (LR−) of 0.21 (95% CI; 0.14–0.30). The pooled diagnostic odds ratio (DOR) was 18 (95% CI; 10–34). The area (AUC) under the hierarchical summary receiver-operating characteristic (HCROC) curve was 0.88 (95% CI: 0.85–0.90). F-18 FDG PET or PET/CT demonstrated moderate sensitivity and specificity for the detection of recurrent and/or metastatic diseases in DTC patients with progressively and/or persistently elevated TgAb levels and negative RI-WBS.

scholarly journals Diagnostic Performance of PET Imaging Using Different Radiopharmaceuticals in Prostate Cancer According to Published Meta-Analyses

Cancers ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 2153 ◽  
Author(s):  
Salvatore Annunziata ◽  
Daniele Antonio Pizzuto ◽  
Giorgio Treglia
Keyword(s):  
Prostate Cancer ◽  
Positron Emission Tomography ◽  
Pet Imaging ◽  
Diagnostic Performance ◽  
Emission Tomography ◽  
Cochrane Library ◽  
Evidence Based ◽  
Positron Emission ◽  
Pet Ct ◽  
Meta Analyses

A significant number of meta-analyses reporting data on the diagnostic performance of positron emission tomography (PET) in prostate cancer (PCa) is currently available in the literature. In particular, different PET radiopharmaceuticals were used for this purpose. The aim of this review is to summarize information retrieved by published meta-analyses on this topic. The first step included a systematic search of the literature (last search date: June 2020), screening two databases (PubMed/MEDLINE and Cochrane Library). This combination of key words was used: (A) “PET” OR “positron emission tomography” AND (B) “prostate” OR “prostatic” AND (C) meta-analysis. Only meta-analyses on Positron Emission Tomography/Computed Tomography (PET/CT) or Positron Emission Tomography/Magnetic Resonance (PET/MR) in PCa were selected. We have summarized the diagnostic performance of PET imaging in PCa, taking into account 39 meta-analyses published in the literature. Evidence-based data showed the good diagnostic performance of PET/CT with several radiopharmaceuticals, including prostate-specific membrane antigen (PSMA)-targeted agents, radiolabeled choline, fluciclovine, and fluoride in restaging and staging settings. Less evidence-based data were available for PET/MR with different radiotracers. More prospective multicentric studies and cost-effectiveness analyses are warranted.

scholarly journals Diagnostic Performance and Prognostic Value of PET/CT with Different Tracers for Brain Tumors: A Systematic Review of Published Meta-Analyses

2019 ◽  
Vol 20 (19) ◽  
pp. 4669 ◽  
Author(s):  
Giorgio Treglia ◽  
Barbara Muoio ◽  
Gianluca Trevisi ◽  
Maria Vittoria Mattoli ◽  
Domenico Albano ◽  
...  
Keyword(s):  
Brain Tumors ◽  
Prognostic Value ◽  
Diagnostic Performance ◽  
Cochrane Library ◽  
Evidence Based ◽  
Pet Tracers ◽  
Positron Emission ◽  
Pet Ct ◽  
Meta Analyses ◽  
The Cochrane Library

Background: Several meta-analyses reporting data on the diagnostic performance or prognostic value of positron emission tomography (PET) with different tracers in detecting brain tumors have been published so far. This review article was written to summarize the evidence-based data in these settings. Methods: We have performed a comprehensive literature search of meta-analyses published in the Cochrane library and PubMed/Medline databases (from inception through July 2019) about the diagnostic performance or prognostic value of PET with different tracers in patients with brain tumors. Results: We have summarized the results of 24 retrieved meta-analyses on the use of PET or PET/computed tomography (CT) with different tracers in brain tumors. The tracers included were: fluorine-18 fluorodeoxyglucose (18F-FDG), carbon-11 methionine (11C-methionine), fluorine-18 fluoroethyltyrosine (18F-FET), fluorine-18 dihydroxyphenylalanine (18F-FDOPA), fluorine-18 fluorothymidine (18F-FLT), and carbon-11 choline (11C-choline). Evidence-based data demonstrated good diagnostic performance of PET with different tracers in detecting brain tumors, in particular, radiolabelled amino acid tracers showed the highest diagnostic performance values. All the PET tracers evaluated had significant prognostic value in patients with glioma. Conclusions: Evidence-based data showed a good diagnostic performance for some PET tracers in specific indications and significant prognostic value in brain tumors.

Diagnostic performance of 18F-FDG PET/CT, ultrasonography and MRI

2014 ◽  
Vol 53 (03) ◽  
pp. 89-94 ◽  
Author(s):  
D. H. Lee ◽  
J.-K Yoon ◽  
S. J. Lee ◽  
T. H. Kim ◽  
D. K. Kang ◽  
...  
Keyword(s):  
Lymph Node ◽  
Fdg Pet ◽  
Axillary Lymph Node ◽  
Diagnostic Performance ◽  
Axillary Lymph ◽  
Diagnostic Ability ◽  
Node Metastasis ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

SummaryThe aim of this study was to evaluate the diagnostic abilities of 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) compared with those of ultrasonography and magnetic resonance imaging (MRI) for axillary lymph node staging in breast cancer patients. Patients, methods: Pre- operative 18F-FDG PET/non-contrast CT, ultrasonography and MRI were performed in 215 women with breast cancer. Axillary lymph node dissection was performed in all patients and the diagnostic performance of each modality was evaluated using histopathologic assessments as the reference standard. ROC curves were compared to evaluate the diagnostic ability of several imaging modalities (i. e., ultrasonography, MRI and 18F-FDG PET/CT). Results: In total, 132 patients (61.4%) had axillary lymph node metastasis. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy for the detection of axillary lymph node metastasis were 72.3%, 77.3%, 66.7%, 81.6%, 75.3% for ultrasonography, 67.5%, 78.0%, 65.9%, 79.2%, 74.0% for MRI, and 62.7%, 88.6%, 77.6%, 79.1%, 78.6% for 18F-FDG PET/CT, respectively. There was no significant difference in diagnostic ability among the imaging modalities (i.e., ultrasonography, MRI and 18F-FDG PET/CT). The diagnostic ability of 18F-FDG PET/CT was significantly improved by combination with MRI (p = 0.0002) or ultrasonography (p < 0.0001). The combination of 18F-FDG PET/CT with ultrasonography had a similar diagnostic ability to that of all three modalities combined (18F-FDG PET/CT+ultraso- nography+MRI, p = 0.05). Conclusion: The diagnostic performance of 18F-FDG PET/CT for detection of axillary node metastasis was not significantly different from that of ultrasonography or MRI in breast cancer patients. Combining 18F-FDG PET/CT with ultrasonography or MRI could improve the diagnostic performance compared to 18F-FDG PET/CT alone.

scholarly journals Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myeloma

2021 ◽  
Author(s):  
Olwen Westerland ◽  
◽  
Ashik Amlani ◽  
Christian Kelly-Morland ◽  
Michal Fraczek ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Clinical Data ◽  
Bone Disease ◽  
Fdg Pet ◽  
Diagnostic Performance ◽  
Whole Body ◽  
Bone Lesions ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Abstract Purpose Comparative data on the impact of imaging on management is lacking for multiple myeloma. This study compared the diagnostic performance and impact on management of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and whole-body magnetic resonance imaging (WBMRI) in treatment-naive myeloma. Methods Forty-six patients undergoing 18F-FDG PET/CT and WBMRI were reviewed by a nuclear medicine physician and radiologist, respectively, for the presence of myeloma bone disease. Blinded clinical and imaging data were reviewed by two haematologists in consensus and management recorded following clinical data ± 18F-FDG PET/CT or WBMRI. Bone disease was defined using International Myeloma Working Group (IMWG) criteria and a clinical reference standard. Per-patient sensitivity for lesion detection was established. McNemar test compared management based on clinical assessment ± 18F-FDG PET/CT or WBMRI. Results Sensitivity for bone lesions was 69.6% (32/46) for 18F-FDG PET/CT (54.3% (25/46) for PET component alone) and 91.3% (42/46) for WBMRI. 27/46 (58.7%) of cases were concordant. In 19/46 patients (41.3%) WBMRI detected more focal bone lesions than 18F-FDG PET/CT. Based on clinical data alone, 32/46 (69.6%) patients would have been treated. Addition of 18F-FDG PET/CT to clinical data increased this to 40/46 (87.0%) patients (p = 0.02); and WBMRI to clinical data to 43/46 (93.5%) patients (p = 0.002). The difference in treatment decisions was not statistically significant between 18F-FDG PET/CT and WBMRI (p = 0.08). Conclusion Compared to 18F-FDG PET/CT, WBMRI had a higher per patient sensitivity for bone disease. However, treatment decisions were not statistically different and either modality would be appropriate in initial staging, depending on local availability and expertise.

Sign in / Sign up

Export Citation Format

Share Document